Clinical Trial Update: The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the effect of BIA 2-093 on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. The trial status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• BIA 2-093
• Phenytoin (Phenytoin)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Epilepsy | Phase 1 | Status: TERMINATED